Objectives/Goals: This research develops a Ruthenium (III)–Fruquintinib complex for lung cancer treatment. Goals include structural characterization using MALDI-TOF and UV–Vis spectroscopy, synthesis optimization, and antitumor activity assessment comparing efficacy against Fruquintinib alone through cell studies. Methods/Study Population: The Ruthenium(III)–Fruquintinib complex is synthesized through an optimized coordination chemistry protocol ensuring reproducibility. Small-scale reactions defined baseline conditions, monitored by UV–Vis spectroscopy for ligand–metal charge transfer. After successful crystallization, the method was scaled up consistently. Structural characterization using MALDI-TOF mass spectrometry will be performed in collaboration with the MSRC, University of Puerto Rico, with infrared spectroscopy as a complementary validation. Biological evaluation will use NSCLC cell lines to compare cytotoxic efficacy against Fruquintinib alone, employing MTT assays to determine IC50 and potential synergistic effects. Results/Anticipated Results: Lung cancer remains the leading cause of cancer-related mortality, with 125,070 projected deaths in 2024. Current treatments for metastatic disease include surgery, chemotherapy, radiation, and targeted therapy. Fruquintinib (FQ), a VEGFR inhibitor, showed promise in early NSCLC trials but limited efficacy in advanced stages. Ruthenium (III) complexes, based on the hard–soft acid–base principle, offer potential anticancer properties. Combining FQ with Ruthenium (III) may enhance therapeutic outcomes. Preliminary synthesis yielded reproducible crystals confirmed by UV–Vis signals. Future MALDI-TOF characterization and biological assays will assess structural validity and antitumor potential. Discussion/Significance of Impact: The Ruthenium (III)–Fruquintinib complex could enhance Fruquintinib efficacy in advanced NSCLC. This approach demonstrates the potential of metal-based drug design to improve cancer therapies, offering insights into combinatorial strategies and advancing coordination chemistry in medicinal research.